6/30/23, 2:16 AM TICH-2 (substudy) Pathway Feedback Search Clinical Topics Home Studies TICH 2 (substudy) TICH 2 (substudy) Disease Intracerebral hemorrhage Trial question What is the role of tranexamic acid on remote cerebral ischemic lesions in acute spontaneous intracerebral hemorrhage? Study design Multi-center Double blinded RCT Population Characteristics of study participants 42.0% female N = 219 58.0% male 219 patients (93 female, 126 male) Inclusion criteria: adults with acute spontaneous intracerebral hemorrhage who underwent MRI Key exclusion criteria: intracranial hemorrhage secondary to anticoagulation; thrombolysis, contraindication to study drug; trauma or a known underlying structural abnormality Interventions N=96 tranexamic acid (1 g in 100 mL intravenous bolus, followed by 1 g in 250 mL infusion within 8 hours of hemorrhage onset) N=123 placebo (0.9% saline within 8 hours of hemorrhage onset) Primary outcome https://web.pathway.md/studies/recCq37fQ22pZ5LCi 1/2 6/30/23, 2:16 AM TICH-2 (substudy) Pathway Diffusion-weighted imaging hypertense lesions 22.8 % 22.8 20.8 17.1 % 11.4 % 5.7 % No significant difference 0.0 % Tranexamic acid Placebo No significant difference in DWI hypertense lesions (20.8% vs. 22.8%; OR 0.71, 95% CI 0.33 to 1.53) Secondary outcomes No significant difference in mean number of DWI hypertense lesions (1.75 vs. 1.81; MD -0.08, 95% CI -0.36 to 0.2) Conclusion In adults with acute spontaneous intracerebral hemorrhage who underwent MRI, tranexamic acid was not superior to placebo with respect to a DWI hypertense lesions. Reference Stefan Pszczolkowski, Nikola Sprigg, Lisa J Woodhouse et al. Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. JAMA Neurol. 2022 May 1;79(5):468-477. Open reference URL https://web.pathway.md/studies/recCq37fQ22pZ5LCi 2/2